Table 1.
Patient baseline characteristics.
| n | % | |
|---|---|---|
| Age | ||
| Median 66 (range 56–82) | ||
| ≤64 years | 2 | 20 |
| 65–69 years | 5 | 50 |
| ≥70 years | 3 | 30 |
| Sex | ||
| Male | 8 | 80 |
| Female | 2 | 20 |
| ECOG PS | ||
| 0 | 6 | 60 |
| 1 | 4 | 40 |
| Cause of HCC a | ||
| HBV | 2 | |
| HCV | 3 | |
| alcohol | 4 | |
| metabolic syndrome | 1 | |
| unknown | 1 | |
| Site of lesions | ||
| Liver | 10 | 100 |
| Extrahepatic disease b | 8 | 80 |
| Lung | 4 | |
| Peritoneum | 5 | |
| Bone | 3 | |
| Lymph nodes | 1 | |
| Soft tissues | 1 | |
| Child–Pugh score | ||
| 5 | 4 | 40 |
| 6 | 6 | 60 |
| ≥7 | 0 | 0 |
| α-fetoprotein ≥ 400 ng/mL | 1 | 10 |
| Previous treatments | ||
| Locoregional therapy c | 9 | 90 |
| Surgery | 7 | |
| Thermal ablation | 5 | |
| TACE | 6 | |
| Systemic therapy | 10 | 100 |
| Sorafenib | 10 | 100 |
| Reason for discontinuation of sorafenib | ||
| Progressive disease | 9 | 90 |
| Toxicity | 1 | 10 |
a One patient had coexisting HCV and alcoholic etiologies. b Some patients had more than one extrahepatic site involved. c Some patients had received more than one locoregional therapy. ECOG PS, Eastern Cooperative Oncology Group Performance Status; TACE, transarterial chemoembolization.